Literature DB >> 27311969

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Solomon A Graf1, Jennifer E Vaughn2, Thomas R Chauncey1, Barry E Storer3, Ajay K Gopal4, Leona A Holmberg4, Jeannine S McCune5, William I Bensinger4, David G Maloney4, Oliver W Press4, Rainer Storb4, Mohamed L Sorror6.   

Abstract

Autologous hematopoietic cell transplantation (HCT) is a treatment option for many patients diagnosed with lymphoma. The effects of patient-specific factors on outcomes after autologous HCT are not well characterized. Here, we studied a sequential cohort of 754 patients with lymphoma treated with autologous HCT between 2000 and 2010. In multivariate analysis, patient-specific factors that were statistically significantly associated with nonrelapse mortality (NRM) included HCT-specific comorbidity index (HCT-CI) scores  ≥ 3 (HR, 1.94; P = .05), a history of alcohol use disorder (AUD) (HR, 2.17; P = .004), and older age stratified by decade (HR, 1.29; P = .02). HCT-CI ≥ 3, a history of AUD, and age > 50 were combined into a composite risk model: NRM and overall mortality rates at 5 years increased from 6% to 30% and 32% to 58%, respectively, in patients with 0 versus all 3 risk factors. The HCT-CI is a valid tool in predicting mortality risks after autologous HCT for lymphoma. AUD and older age exert independent prognostic impact on outcomes. Whether AUD indicates additional organ dysfunction or sociobehavioral abnormality warrants further investigation. The composite model may improve risk stratification before autologous HCT. Published by Elsevier Inc.

Entities:  

Keywords:  Alcohol; Autologous; HCT-CI; Lymphoma; Transplant

Mesh:

Year:  2016        PMID: 27311969      PMCID: PMC4981519          DOI: 10.1016/j.bbmt.2016.06.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  35 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 2.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

3.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

4.  High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.

Authors:  Dai Chihara; Koji Izutsu; Eisei Kondo; Rika Sakai; Shuichi Mizuta; Kenji Yokoyama; Hiroto Kaneko; Koji Kato; Yuichi Hasegawa; Takaaki Chou; Hiroyuki Sugahara; Hideho Henzan; Hisashi Sakamaki; Ritsuro Suzuki; Junji Suzumiya
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-31       Impact factor: 5.742

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Substance abuse and bone marrow transplant.

Authors:  G Chang; J H Antin; E J Orav; U Randall; C McGarigle; H M Behr
Journal:  Am J Drug Alcohol Abuse       Date:  1997-05       Impact factor: 3.829

7.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Mohamed L Sorror; Brent R Logan; Xiaochun Zhu; J Douglas Rizzo; Kenneth R Cooke; Philip L McCarthy; Vincent T Ho; Mary M Horowitz; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

8.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

Review 9.  Psychosocial factors and hematopoietic stem cell transplantation: potential biobehavioral pathways.

Authors:  Jennifer M Knight; Jeffrey M Lyness; Olle Jane Z Sahler; Jane L Liesveld; Jan A Moynihan
Journal:  Psychoneuroendocrinology       Date:  2013-07-08       Impact factor: 4.905

10.  The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Authors:  L Farina; B Bruno; F Patriarca; F Spina; R Sorasio; M Morelli; R Fanin; M Boccadoro; P Corradini
Journal:  Leukemia       Date:  2009-02-05       Impact factor: 11.528

View more
  3 in total

1.  Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study.

Authors:  Bente Arboe; Maja Halgren Olsen; Jette Sønderskov Gørløv; Anne Katrine Duun-Henriksen; Susanne Oksbjerg Dalton; Christoffer Johansen; Peter de Nully Brown
Journal:  Clin Epidemiol       Date:  2019-03-04       Impact factor: 4.790

2.  The impact of pulmonary function in patients undergoing autologous stem cell transplantation.

Authors:  Jesús Duque-Afonso; Sophie Ewald; Gabriele Ihorst; Miguel Waterhouse; Tim Struessmann; Robert Zeiser; Ralph Wäsch; Hartmut Bertz; Joachim Müller-Quernheim; Justus Duyster; Jürgen Finke; Reinhard Marks; Monika Engelhardt
Journal:  Blood Adv       Date:  2021-11-09

3.  Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population.

Authors:  Dylan Barth; Michael Singleton; Gregory Monohan; Brian McClune; Val Adams
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.